Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MS patients may get symptom relief from simple nurse education – even online

NCT ID NCT07411508

Symptom relief Sponsor: ugurlu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether education from a nurse – either in person or through tele-nursing (like WhatsApp) – can help people with multiple sclerosis feel less tired, have less pain, sleep better, and get fewer urinary tract infections. About 96 adults with relapsing-remitting MS will receive training modules over six weeks. The goal is to see if this supportive education improves daily life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nurse-led education (face-to-face or tele-nursing)
What this could lead to
If successful, this could show that remote nursing education is as good as in-person sessions for managing MS symptoms, offering a convenient option for patients.
What could go wrong
This is a small, single-center trial with only 96 participants, so results may not apply to everyone. The education is supportive, not a treatment for the disease itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

96 people

The number who actually took part.

Started

Apr 2024

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who are willing to participate in the study, * Age between 18-55, * Literate, * Diagnosed at least 1 year ago, * Diagnosed with Relapsing-Remitting MS (the most common type, RRMS, which progresses with attacks and remissions), * A specialist (psychologist or psychiatrist) has determined that their cognitive level is suitable for participation in the study, * Scoring their pain 4 points or higher on the Visual Analog Scale (VAS), * Scoring 4 or higher on the Fatigue Severity Scale (FSS), * Scoring 10 or higher on the Epworth Sleepiness Scale (ESS), * Having not used any other complementary and alternative treatments in the last 6 months, * Patients who own or have a family member who owns a smartphone, tablet, or computer will be included (Eren, 2018). Exclusion Criteria: * Patients who are unwilling to participate in the study for any reason, * Have a communication disability, * Have a hearing or visual impairment, * Have failed to attend three consecutive training sessions unless medically indicated, * Have not completed 70% of the training program (or 17 of 24 sessions) (Alonso Martínez et al., 2023), * Have developed serious physical or mental illnesses during the study period, * Have been found to be unsuitable for participation in the study (as assessed by a psychologist or psychiatrist), * Have used other complementary therapies such as acupuncture, yoga, meditation, etc. during the study period, * Have been in an attack phase of the disease or have conditions requiring hospitalization during the intervention will not be included in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Education are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fatigue multiple sclerosis Pain relapsing-remitting multiple sclerosis urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Education Multiple sclerosis Symptom management

Contacts and locations

Locations

  • Sakarya University Institute of Health Sciences

    Sakarya, Serdivan, 54050, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.